Intuitive Surgical, Inc. (NASDAQ:ISRG) was less active in the last trading session as around 0.58 million shares exchanged hands on Wall Street, representing a decrease from its normal capacity of 0.82 million shares. A -0.33% change after the initial price of $390.25, sent the closing price to $389.69.Intuitive Surgical, Inc. (ISRG) Analyst Opinion
Intuitive Surgical, Inc. has a consensus outperform rating from 18 Wall Street analysts, and the number of shares currently sold short amount to at least 3.75% of shares outstanding. The stock spiked 9.77% last month and is up 84.35 this year. Wall Street is only getting more bullish on the stock, with 11 of analysts who cover ISRG having a buy-equivalent rating. Analysts have placed a $372.56 price target on Intuitive Surgical, Inc., suggesting a -4.4% decline from recent close. It’s currently trading about -0.97% below its 52-week high.
Intuitive Surgical, Inc. (ISRG) surprised the stock market in its last reported earnings when it earned $2.77 a piece versus the consensus-estimated $1.99. Its revenue totaled $753.15 million down -0.4% from the previous quarter.Intuitive Surgical, Inc. (NASDAQ:ISRG) Intraday View
This stock (ISRG) is ahead of its 52-week low with 91.43%. Its last month’s stock price volatility remained 1.28% which for the week stands at 1.65%. The share price has moved forward from its 20 days moving average, trading at a distance of 3% and stays 7.75% away from its 50 days moving average. Over the last five days, shares have faced -0.68% losses and now is up 27.99% since hitting its 200-day moving average of $328.24. Intuitive Surgical, Inc. (ISRG) has made its way to a 12-month gain of 82.51%.
Turning to Intellia Therapeutics Inc. (NASDAQ:NTLA), its shares were trading at $19.55 a gain of $0.21, on the trading floor. The stock, after opening at $19.19, touched a high of $20.11 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.8. Intellia Therapeutics Inc. has 3 buy ratings, 2 holds and 0 sells even after the stock tumbled -41.36% from its high of $33.34 to a $685.23 million market value through last close.
The company’s consensus rating on Reuter’s scale slipped from 1.86 to 1.83 during a month. Analysts set a 12-month price target of $32.67 a share. The target implies a 67.11% spike from where the shares are currently trading. Also, the current price highlights a discount of 114.83% to analysts’ high consensus price target.Intellia Therapeutics Inc. (NASDAQ:NTLA) Intraday Trading
The counter witnessed a trading volume of 0.5 million shares versus an average volume of 0.57 million shares during last trading session. Its last month’s stock price volatility remained 7.4% which for the week approaches 7.73%. The lowest price the stock reached in the last trading day was $19 and compares with the $10.83 52-week low. The stock recovered 80.52% since its low point and has performed 49.12% year-to-date.